Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02935634) enrolled a total of 190 participants across six treatment groups, testing different combinations of cancer medicines — including nivolumab, ipilimumab, BMS-986016 (relatlimab), BMS-986205, rucaparib, and combinations of these — in people with advanced cancers. The trial used two separate pathways (called "Track 1" and "Track 2"), and participants could move between tracks depending on how their disease responded. The trial was primarily measuring how many participants' tumours shrank or disappeared (called the objective response rate), how long that response lasted, and how many participants remained free of disease progression at 24 weeks. The reported data shows that the proportion of participants whose tumours shrank or disappeared varied across the treatment groups and tracks. In Track 1, the reported response rates ranged from 0% (in the nivolumab + rucaparib and ipilimumab + rucaparib groups) up to 16.7% in the nivolumab + ipilimumab + rucaparib group. In Track 2, response rates ranged from 0% in several groups up to 8.7% in the nivolumab + ipilimumab group. For how long responses lasted, the reported data was only available for some groups — for example, in Track 1, the nivolumab + ipilimumab group reported a median response duration of 156 weeks, while in Track 2 the nivolumab + ipilimumab group reported approximately 14.7 weeks and the nivolumab + BMS-986016 group approximately 16.9 weeks; duration data was not reported for several other groups. For the 24-week progression-free survival rate, figures were only reported for two groups: Track 1 nivolumab + BMS-986205 (0.24, meaning about 24 in every 100 participants) and Track 2 nivolumab + BMS-986016 (0.17, meaning about 17 in every 100 participants); this figure was not reported for the remaining groups. The reported data also shows that adverse events (unintended medical occurrences during the trial) and serious adverse events were recorded across all groups, with numbers reflecting the size of each group. Thyroid and liver test abnormalities were also measured and reported across groups, with varying numbers of participants affected in each. The raw counts for these findings are listed in the submitted results, but no further detail about the nature or severity breakdown was included in the data available here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Stomach Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with esophageal cancer, stomach cancer, or cancer at the junction between the esophagus and stomach that cannot be removed by surgery, has spread locally, or has spread to other parts of the body, and the cancer type has been confirmed by a tissue sample as adenocarcinoma and/or squamous carcinoma
- You are generally well enough to carry out light activity and care for yourself, meaning you are not bedridden or severely limited in daily activities (confirm with trial site)
- You have at least one area of cancer that can be measured on a scan
Who may not be able to join:
- Your cancer tests positive for a protein called HER2, and you have not yet been treated with a drug called trastuzumab (Herceptin)
- There is any suspicion, confirmed evidence, or new growth of cancer that has spread to the brain or spinal cord
- You currently have another active cancer that needs treatment at the same time
- You have an active autoimmune disease, which is a condition where your immune system mistakenly attacks your own body (such as rheumatoid arthritis or lupus)
Important: There are additional eligibility requirements not listed here. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Objective Response Rate (ORR) by Investigator; Median Duration of Response (DOR); Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.